Article
Excerpt from the Press Release: SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that the company has received clearance from the FDA for the company’s Investigational New Drug (IND) application for the combination of…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy approaches initially focused on non-invasive detection of high-mortality cancers, today announced positive performance evaluation study results for its pancreatic cancer test. These data confirm that its pancreatic cancer test detects the…
Read More
–FDA States Pivotal Clinical Trial May Proceed, Trial Expected to Commence By March 2022– Excerpt from the Press Release: PHILADELPHIA, Jan. 21, 2022 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that they have completed the safety review of the Investigational New…
Read More
— Single-cell proteomics can elucidate kinase activity in prostate cancer models — — Kinase activity in bone metastases and epithelial circulating tumor cells is elevated — Excerpt from the Press Release: BEVERLY, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) — TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection of cancer through its…
Read More
– FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome – – KOMET-001 study to resume screening and enrollment of new patients – – Encouraging safety, tolerability and clinical activity observed among patients on study – Excerpt from the Press Release: SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) — Kura Oncology,…
Read More
Five-year collaboration to provide support for clinical and preclinical efforts as Yingli Pharma expands its U.S. presence with robust oncology pipeline Excerpt from the Press Release: SAN FRANCISCO and HOUSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) — Yingli Pharma US, Inc. (the “Company” or “Yingli”), a biotechnology company developing innovative small molecules, and The University of…
Read More
Innovative study deployed multiplexed ion beam imaging (MIBI™) technology revealing a high-multiplex spatial proteomic signature as a predictive biomarker for breast cancer treatment Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Ionpath, Inc., the leader in high-definition spatial proteomics, today announced that a peer-reviewed research study led by scientists at Stanford University, Washington University, Duke…
Read More
Excerpt from the Press Release: BRISBANE, Calif. and ST. LOUIS, Jan. 21, 2022 (GLOBE NEWSWIRE) — Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to AO-176 on January 3rd, 2022, for the…
Read More Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–IncellDx, a precision medicine company, today announced the journal Frontiers in Immunology has published a study detailing a framework for understanding the potential mechanism of, and potential treatment for, Post-Acute Sequelae of COVID-19 (PASC), also known as long COVID or long haul COVID. “Recent analysis confirms long…
Read More
Excerpt from the Press Release: WALTHAM, Mass. & LAKELAND, Fla.–(BUSINESS WIRE)–BostonGene Corporation and WellDyne today announced a strategic partnership to improve therapeutic decision-making for cancer patients. With BostonGene Tumor Portrait™ Tests, WellDyne will increase efficiency and therapy selection for patients who are candidates for immunotherapy in melanoma, non-small cell lung cancer, gastric, bladder and kidney…
Read More